FLASCO

 

Corporate Members

Diamond Elite

Diamond

Platinum

Gold

Silver

Latest News

Guidelines for Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline

Edgardo S. Santos Castillero, M.D., FACP, Secretary of the Florida Society of Clinical Oncology (FLASCO), Founding Partner, Florida Precision Oncology R&C, FPO, a Division of 21st Century Oncology Thoracic and Head/Neck Cancer Programs, and Clinical Associate Professor at Charles E. Schmidt College of Medicine, Florida Atlantic University shared his appreciation of the opportunity provided by ASCO to him and his Co-Chairs...

New Standards/Guidelines to Dispense Oral Medications

Luis E. Raez, MD, FACP, FCCP, President of Florida Society of Clinical Oncology (FLASCO), Chief Scientific Officer & Medical Director of Memorial Cancer Institute, Memorial Health Care System and Clinical Professor of Medicine at the Herbert Wertheim College of Medicine, Florida International University participated in the Expert Panel created by the American Society of Clinical Oncology (ASCO) and the National Community Oncology Dispensing...

Info on accelerated approval for BRUKINSA

Please be aware NCCN has recently updated their Oncology Guidelines for Mantel Cell Leukemia (MCL) based on the accelerated approval for BRUKINSA. NCCN has provided BRUKINSA (zanubrutinib) in R/R MCL with a Level 2A Preferred evidence listing, comparable to other BTKi in the class. This is the link to the NCCN main website, https://www.nccn.org/professionals/physician_gls/default.aspx . 

Signatera Test to Assess Residual Disease

Signatera is a personalized, tumor informed circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) assessment and surveillance monitoring. Signatera’s unique assay design is optimized to detect low levels of ctDNA with high sensitivity and specificity earlier than current colorectal cancer (CRC) standard of care. Signatera recently received Medicare draft coverage for certain forms...

Outcome of BRCA Survey Project

In July 2019, the FLASCO Board of Directors approved a Survey Initiative on BRCA testing with Merck, FLASCO Diamond Elite Member. All FLASCO Members who treat patients with breast/ovarian cancer, including APPs, were asked to complete the survey.  The goal of the project was to identify the needs in order to increase awareness and utilization...

Who’s Online

Profile picture of FLASCO